S&P 500   4,513.04
DOW   34,022.04
QQQ   387.12
S&P 500   4,513.04
DOW   34,022.04
QQQ   387.12
S&P 500   4,513.04
DOW   34,022.04
QQQ   387.12
S&P 500   4,513.04
DOW   34,022.04
QQQ   387.12
NASDAQ:RNAZ

TransCode Therapeutics News Headlines

$2.70
-0.05 (-1.82%)
(As of 12/1/2021 12:00 AM ET)
Add
Compare
Today's Range
$2.64
$3.10
50-Day Range
$2.45
$4.02
52-Week Range
$2.35
$7.00
Volume
308,802 shs
Average Volume
2.93 million shs
Market Capitalization
$34.84 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A

Media Mentions By Week



TransCode Therapeutics Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

RNAZ
News Sentiment

0.99

0.29

Average
Medical
News Sentiment

Media Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

RNAZ Articles
This Week

2

0

RNAZ Articles
Average Week

Get TransCode Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for RNAZ and its competitors with MarketBeat's FREE daily newsletter.

TransCode Therapeutics (NASDAQ:RNAZ) News Headlines Today

SourceHeadline
MarketBeat logoTransCode Therapeutics, Inc. (NASDAQ:RNAZ) Short Interest Update
americanbankingnews.com - November 27 at 11:34 AM
MarketBeat logoTransCode Therapeutics, Inc. (NASDAQ:RNAZ) Short Interest Down 22.9% in October
americanbankingnews.com - November 20 at 3:38 PM
finance.yahoo.com logoCompanies Like TransCode Therapeutics (NASDAQ:RNAZ) Are In A Position To Invest In Growth
finance.yahoo.com - November 18 at 2:08 PM
finance.yahoo.com logoTransCode Therapeutics Reports Business Progress and Third Quarter 2021 Financial Results
finance.yahoo.com - November 15 at 5:46 PM
finance.yahoo.com logoTransCode Therapeutics Announces Participation in the Q4 Virtual Investor Summit
finance.yahoo.com - November 9 at 9:02 AM
finance.yahoo.com logoTransCode Therapeutics Appoints Zdravka Medarova, Ph.D., as Chief Technology Officer
finance.yahoo.com - September 30 at 4:35 PM
finance.yahoo.com logoWhy Are TransCode Therapeutics Shares Shooting Higher On Thursday?
finance.yahoo.com - September 23 at 3:19 PM
nasdaq.com logoTransCode: Preclinical Data Supports Therapeutic Potential Of TTX-MC138 In Metastatic Breast Cancer
nasdaq.com - September 23 at 10:18 AM
finance.yahoo.com logoTransCode Therapeutics Announces Publication in Cancer Nanotechnology of Preclinical Data Supporting Therapeutic Potential of TTX-MC138 in Metastatic Breast Cancer
finance.yahoo.com - September 23 at 10:18 AM
nasdaq.com logoTransCode Therapeutics Inc Shares Fall 2.5% Below Previous 52-Week Low - Market Mover
nasdaq.com - September 21 at 12:52 AM
finance.yahoo.com logoTransCode Therapeutics Reports Business Progress and Second Quarter 2021 Financial Results
finance.yahoo.com - August 23 at 8:16 PM
barrons.com logoTransCode Therapeutics Inc.
barrons.com - August 21 at 3:46 PM
finance.yahoo.com logoTransCode Therapeutics Awarded Funding from National Institutes of Health (NIH) to Support Clinical Evaluation of TTX-MC138
finance.yahoo.com - August 5 at 7:49 AM
finance.yahoo.com logoTransCode Therapeutics, Inc. Announces Pricing of Initial Public Offering
finance.yahoo.com - July 13 at 9:32 PM
finance.yahoo.com logoChinese Fintech Sentage Pops Nearly 600% in Market Debut
finance.yahoo.com - July 13 at 9:32 PM
finance.yahoo.com logoTransCode Therapeutics, Inc. Announces Closing of Initial Public Offering, Including Full Exercise of Underwriters' Over-allotment Option
finance.yahoo.com - July 13 at 9:32 PM
Get TransCode Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for RNAZ and its competitors with MarketBeat's FREE daily newsletter.

This page was last updated on 12/2/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.